An overview of key considerations shaping the BGM and CGM decision, why both often coexist in trials today, and how eCOA platforms play a critical role in supporting this data collection at scale.
Karl McEvoy, PhD, and Aubrey Verna
Advertisement
Articles by Karl McEvoy, PhD, and Aubrey Verna
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials
2
HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure
3
Where AI Leads in Trial Design—and Where Humans Still Need To
4
What an AI-Informed Approach Means for How Sponsors Think About Risk
5